The ACS Princeton Section and The ACS Philadelphia Section Presents
“Non-Traditional Careers: A Panel Discussion And Networking Event”
Thursday, May 11, 2017, 5:30 pm – 10:00 pm, Bowen Hall Princeton University, Princeton, NJ
Mr. J. P. Northrop (Edward Jones Investments)
MODERATOR: Joe Martino (ACS Career Consultant and Presenter)
COST: $25.00 (Includes dinner) Free if attending only the panel discussion.
To register and for more information, please visit https://acsprincetonphillycareerdiscussion.eventbrite.com
If you have any questions, contact firstname.lastname@example.orgAre you considering stepping away from a traditional chemistry environment and moving toward an exciting career outside of an industrial laboratory? If this describes your situation, then please join us for this informative panel discussion as Joe Martino moderates a conversation with experienced chemists who have done exactly that. We’ll explore transitioning from the industrial laboratory to roles which support the industrial enterprise, academia, non-profits, and even transitioning away from chemistry. Ample opportunity for networking will be provided along with an enjoyable dinner. Please join us!
Bowen Hall is on the campus of Princeton University near the corner of Prospect Avenue and Olden Street. There will be a social mixer at 5:30 pm in the second floor Atrium, directly outside of the Auditorium (Room 222). The lecture will begin in the Auditorium at 6:15 pm and dinner will follow in the Atrium. Bowen Hall is readily accessible from US 1, US 206, NJ 27, I 95 and I 295. Free parking is available beginning at 5:00 PM in the North Garage which is right next to Bowen Hall.
Kevin Cannon, PhD is currently a professor at Penn State Abington College (14th year) and an assistant adjunct professor at Temple University (25th year). His research interests include both heterocyclic chemistry and the history of science. He earned a B.A. and Ph.D. in chemistry from Temple University and Princeton University respectively; he was a post-doctoral fellow at the University of Texas at Austin. Prior to becoming a full-time faculty member at Penn State in 2003, Kevin worked nearly 15 years as an industrial chemist, spending 3.5 years at the Dow Chemical Company (Freeport, TX) and the remaining time at Elf Atochem/Atofina/Arkema (King of Prussia, PA). Throughout most of his industrial career, Kevin taught chemistry as an adjunct at local colleges and universities, including Chestnut Hill College and Philadelphia University. Kevin occasionally teaches short courses at the Wagner Free Institute in Philadelphia.
Mukund Chorghade, PhD is a serial entrepreneur, President and Chief Scientific Officer, THINQ Pharma / THINQ Discovery. He is the CSO of Chicago Discovery Solutions, and has had Adjunct Research Professor / Visiting Fellow / Scientists appointments at Harvard, MIT, Princeton, Cambridge, Caltech, Univ. of Chicago, Northwestern, Strathclyde and several other universities. He provides synthetic chemistry and pharmaceutical drug development expertise to academic laboratories, pharmaceutical and biopharmaceutical companies. His current research interests are in Traditional Medicine derived New Chemical Entities and the discovery of the new “chemosynthetic livers” with utility in drug metabolism, valorization of biomass and environmental remediation. He is a Certified CGLP / cGMP professional.
Dr. Chorghade earned his B. Sc. and M. Sc. degrees from the University of Poona, and a Ph. D. at Georgetown University. He completed postdoctoral appointments at the University of Virginia and Harvard University.
Molly Hoke, PhD joined Mallinckrodt Pharmaceuticals, Inc. in November 2016 as a Manager of Scientific Communications where she oversees strategic and tactical execution of a wide variety of scientifically-related deliverables for 3 key brands for the company- INOmax, Therakos, and terlipressin.
Prior to joining Mallinckrodt, she was a Medical Director at DWA Healthcare Communications Group. In this remotely-based role, she served as the client-facing and medical lead on the multimillion dollar Otsuka/Lundbeck agency vertical comprising several neuroscience brands. She has also served similar roles at several other agencies including AdMed, Inc, Synapse Medical Communications, and Harrison and Star
Prior to transitioning into Medical Communications, Molly spent a decade at Wyeth Research in Princeton, NJ as a Senior-level Research Scientist in the Discovery Synthetic Chemistry Group. Molly holds a BS in Chemistry from Gettysburg College and a PhD in Organic Chemistry from The University of Maryland at College Park. She also graduated from the Rutgers mini-MBA program in Global BioPharma Entrepreneurship.
J.P. Northrop is a Financial Advisor for Edward Jones Investments in Lansdale, PA. He helps clients and small businesses handle long term financial goals and dreams. He often conducts educational seminars and workshops in and around the Philadelphia region.
Prior to Edward Jones, J.P. was the Senior Technical Sales Representative for Anton Paar USA’s Brewery Operations Group (10 years). He was responsible for sales and assists the technical support group on all US brewery clients.
Before Anton Paar, J.P. worked as a technical sales rep for Shimadzu Scientific and Isco, Inc Prior to Isco, he worked in the lab as a medicinal chemist for the Metabolic Diseases Group of Bristol-Myers Squibb in Princeton, New Jersey
J.P. has an BS in Polymer Chemistry from The College of William and Mary in Virginia (1996). He has a Master’s Degree in Organic Chemistry from the University of Delaware (1999) as well as a Master’s of Business Administration in Finance from the Fox School of Business, Temple University, Pennsylvania (2004). He also holds a Certification in Brewing Science from the University of California – Davis (2012).
Allen N. Jones, Ph.D. received his B.S. in chemistry from Elizabethtown College and Ph.D. from the State University of New York in Buffalo, NY. In his first post-graduate position, he worked for the Veterans Administration in Nuclear Medicine Research to develop novel kidney and cardiac imaging agents. After a brief stint at the University of Connecticut Medical School, he joined Merck and Company in Animal and Exploratory Drug Metabolism (later Drug Metabolism and Pharmacokinetics), where he worked in and managed the Analytical Laboratory for the Isotope Labeling Group. In this position he contributed to the development of experimental drug candidates, a number of which became marketed pharmaceuticals, including Zocor, Mectazin, Cansidas, Fosamax, Vioxx, Crixivan, Singulair, and Januvia. After leaving Merck in 2008 as an Associate Director, he worked with YourEncore as a Network Expert, was an Adjunct Professor at Rowan University, worked at Roche as a Pharmacokinetics Study Manager, at Alliance Technologies as a Senior Chemist, and with Liquid Light as an Analytical Group Leader. Currently he volunteers with Students 2 Science in East Hanover, NJ.
Allen has been a member of the ACS for over 35 years. He is a volunteer AC Career Consultant and is actively involved with the NJACS Drug Metabolism and Mass Spec Topical Groups. He is a member of the Princeton Section of the ACS where he is a Councilor, and helps with many Outreach programs.